Differentiating Novel Classes of Immunotherapy for Advanced Melanoma
CE Information
0.5 CE credits (0.2 pharmacology)Completion Time
30 minutesAvailable Until
May 30, 2024Posted By
Prime CE
Navigate
Overview
Specialties
OncologySubspecialties
OncologyClinical Topics
MelanomaIntended Audience: Oncologists and their clinical teams (PAs, NPs, nurses, and pharmacists) caring for patients with melanoma
Recent advances in the melanoma therapeutic landscape offer a chance for enhanced treatment personalization to improve outcomes for patients with advanced melanoma. However, keeping up with the latest clinical evidence for current and emerging therapies for melanoma remains a challenge.
Tune in for Part 1 of this 2-part series for an in-depth review of:
- Novel classes of immunotherapy and unique mechanism of actions for treatment of advanced melanoma
- The latest safety and efficacy data of new and emerging treatments
- Adverse event management with tumor infiltrating lymphocyte (TIL) therapy
This activity is delivered in partnership with the Melanoma Research Alliance.
Learning Objectives
- Describe the mechanisms of action of new and emerging immune checkpoint inhibitors and adoptive T cell therapies
- Evaluate clinical safety and efficacy data for current and emerging immune checkpoint inhibitors and adoptive T cell therapies used to treat patients with advanced and metastatic melanoma
Speakers
Fox Chase Cancer Center
Vice Chair of Clinical Research
Director, Phase 1 Developmental Therapeutics Program
Director, Medical Oncology Melanoma Program
Dr. Olszanski serves as the Vice Chair of Research at Fox Chase Cancer Center. Philadelphia PA, and he is the Director of the Early Clinical Drug Development Phase I Program at FCCC, and the co-director of the Cutaneous Oncology Program. He has been the principal investigator on over 80 trials. In addition to his focus on cutaneous malignancies, he also treats patients with lung cancer. He represents Fox Chase Cancer Center on the NCCN Melanoma panel and the Management of Immunotherapy-Related Toxicities panel. He is also an associate editor of JNCCN.
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic & Research Institute, a Cedars Sinai Affiliate
Los Angeles, CA
Omid Hamid, MD, is the chief of the Translational Research and Immuno-Oncology Department at The Angeles Clinic and Research Institute and serves as the director of the Melanoma and Phase I Programs. Academic Title as Professor, Department of Medicine at Cedars-Sinai Medical Center. His areas of expertise include immunotherapy and Phase I drug development. He received his medical degree from the University of Southern California (USC) Keck School of Medicine. He completed his internship and residency at the Los Angeles County Hospital USC Medical Center and his fellowship at the Los Angeles County Hospital USC Norris Comprehensive Cancer Center. He is board certified in medical oncology. His research focus involves manipulation of a patient's immune system to attack cancer cells and maintain continuously elevated levels of immunity. He is recognized as one of the preeminent immuno-oncologists and melanoma specialists in the world. He has published extensively and has been at the forefront of the development of paradigm shifting breakthroughs including BRAF/MEK targeted agents, AntiCTLA4, antiPD1, and PDL1 therapies. His current interests include new immunotherapeutic options for patients including bi-specific antibodies, Adoptive T-cell Therapy, and oncolytic therapies with a focus on combinatorial approaches resulting in potentially greater patient benefit. Through his leadership, The Angeles Clinic has fostered a program that combines expert clinical care with teaching and leading clinical research.
CE Information
This activity offers 0.5 CE credits (0.2 pharmacology) to attendees.
Nurse Practitioner Accreditation Statement
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0.2 hour of pharmacology).
Disclosures
*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.
The following individuals have identified relevant financial relationships with ineligible companies to disclose:
-
Anthony J. Olszanski, RPh, MD (Speaker)
Advisory Board or Panel – Bristol-Myers Squibb, Eisai, InstilBio, Merck, Nektar, Novartis, Takeda
Consultant – Pfizer -
Omid Hamid, MD (Speaker)
Advisory Board or Panel – Alkermes, Amgen, Beigene, Bioatla, Bristol-Myers Squibb, Esai, Georgiamune, GigaGen, GlaxoSmithKline, Grit Bio, IO Biotech, Idera, Immunocore, Incyte, Instilbio, Iovance, Janssen, KSQ, Merck, Moderna, Novartis, Obsidian, Pfizer, Regeneron, Roche-Genentech, Sanofi, Seattle Genetics, Tempus, Vial Health, Zelluna
Consultant – Alkermes, Amgen, Beigene, Bioatla, Bristol-Myers Squibb, Esai, Georgiamune, GigaGen, GlaxoSmithKline, Grit Bio, IO Biotech, Idera, Immunocore, Incyte, Instilbio, Iovance, Janssen, KSQ, Merck, Moderna, Novartis, Obsidian, Pfizer, Regeneron, Roche-Genentech, Sanofi, Seattle Genetics, Tempus, Vial Health, Zelluna
Speakers Bureau or other Promotional Education – Bristol-Myers Squibb, Immunocore, Novartis, Pfizer, Regeneron -
Christina Mactal Haaf, PharmD, BCOP (Moderator)
Advisory Board or Panel – BTG Specialist Pharmaceutical, EUSA Pharma LLCThe relationships reported above are related to the following therapeutic area: Oncology
The following individuals have no relevant financial relationships with ineligible companies to disclose:
- Lisa Wakefield, MSN, APRN, FNP-BC (Reviewer)
- Michele B Kaufman, PharmD, BCGP (Planner)
- Annette Sophin, MSMM, PA-C (Planner)
All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.
Funding Disclosure
This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Iovance Biotherapeutics.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity